What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Richard Conway RichardPAConway
3 years 6 months ago
Tomelleri @tomelleri_a et al. GCA. Tocilizumab weekly x 1 year, then every other week x 1 year, then stop. 2 PMR flares during toc. 1 month post-stop 100% remission. 6 months post-stop 24% GCA flare! Some patients seem to need indefinite toc @RheumNow #EULAR2022 POS0266 https://t.co/8I5GQ08HDr
David Liew drdavidliew
3 years 6 months ago
Long-term low-dose steroids for RA: can it be weaned?
Weaning after 2y of blinded add-on in RA:
either PNL 5mg/d or placebo
No substantial evidence of adrenal insufficiency
- symptoms same
- cortisol/ACTH same
It's never too late to wean the pred!
OP0270 #EULAR2022 @RheumNow https://t.co/jp2ZOlAEnb
Aurelie Najm AurelieRheumo
3 years 6 months ago
🧫 JAKi and NK
cells activation:
JAKi and particularly TOFA impacts NK cells:
*phenotype
*function
*impairs the control of proliferation of lung cancer and lymphoma cell lines
An explanation for the increase of cancer events in ORAL surveillance?
@RheumNow #EULAR2022 OP0265 https://t.co/LzMLdzcsDU
Janet Pope Janetbirdope
3 years 6 months ago
MACE events no diff in German RA Rabbit registry of only humans shows #baricitinib and #tofacitinib vs #TNFis @RheumNow @eular_org #EULAR2022 OP0135 https://t.co/O8iOA7jpal
Eric Dein ericdeinmd
3 years 6 months ago
#EULAR2022 OP0274
Hospitalization for TB and other opportunistic infxn (OI) w inflamm joint disease:
⭐️9% with RA, 6% with PsA and AS in Western Australia
⭐️Decrease overall since 1985, but recent increase
⭐️Sharp rise of mycotic infections
⭐️No PJP, likely due to ppx
@Rheumnow
TheDaoIndex KDAO2011
3 years 6 months ago
Low socioeconomic status should on the list as a high risk factor (#notJUSTrace) https://t.co/zikGGLISSN
Richard Conway RichardPAConway
3 years 6 months ago
Yoshimura et al. 10 year findings of TOMORROW study. Glucocorticoid use of even 2mg/day is fracture risk in RA! @RheumNow #EULAR2022 POS0631 https://t.co/c8uCdPzUiE
David Liew drdavidliew
3 years 6 months ago
Visual symptoms in GCA: should we take it on face value?
@cmukhtyar group tertiary rheum/ophthal
n=350 consecutive GCA pts diagnosed (bx/PET)
visual symptoms 29%
ocular signs 13%
Not all symptoms = signs
No doubt not all symptoms of same concern
POS0810 #EULAR2022 @RheumNow https://t.co/TYHylpBhkN
Mrinalini Dey DrMiniDey
3 years 6 months ago
@Yuz6Yusof on breakthrough infections & severe #COVID in RTX treatment #EULAR2022
🦠Rate of mod/severe COVID infection comparable to pre-pandemic severe infection rate
💉High vaccination rate prevented severe disease
📊Consider #comorbidities & low IgG in risk-benefit assessment https://t.co/PGUVbHD7i2
Aurelie Najm AurelieRheumo
3 years 6 months ago
BE COMPLETE RCT
Bimekizumab vs. PBO in TNFiIR PsA pts
meets its primary criteria at 16wks w/
-ACR50 43%
-PASI 90 69%
and MDA achieved in 40+% pts
No new safety signal.
@RheumNow #EULAR2022 OP0255 https://t.co/QazYlzDqIc
Dr. John Cush RheumNow
3 years 6 months ago
Study of 184 #SLE pts shows that major infections in SLE results in a 7 fold increased risk of a major lupus flare. Abst# OP0143 #EULAR2022 https://t.co/yMJcMAFSh6
David Liew drdavidliew
3 years 6 months ago
RA & dementia - it's getting more damning
RA dementia risk: HR 1.25
from Korean nationwide data: RA n=138,592
this follows @MyasoedovaElena's data
RA systemic inflamm leading to dementia (AD, vascular)?
Need to understand if any DMARD protective
OP0271 #EULAR2022 @RheumNow https://t.co/4V7fOtVlnj
Richard Conway RichardPAConway
3 years 6 months ago
Merola et al. IL23i Risankizumab in PsA. Proportion achieving ACR20 week24 by subgroup. Effective across all groups. Similar irrespective of demographics, disease characteristics, concomittent meds, prior bDMARD use. @RheumNow #EULAR2022 POS1032 https://t.co/GAVKFpwCst
Eric Dein ericdeinmd
3 years 6 months ago
#EULAR2022 OP0275: RA-ILD after transplant by @AARazmjou
⭐️UIP #1 cause RA-ILD, worst prognosis - 68% of transplanted pts
⭐️UIP seen in 88% of deceased patients, 56% of living
⭐️Median survival 5.3 years
@RheumNow https://t.co/tGBQ5GBlVg
TheDaoIndex KDAO2011
3 years 6 months ago
Promising! Prof Schett presents the 1st 5 #SLE pts who received CAR T cell therapy - all went into sustained remission off of meds: new B cells reconstituted at 100 days but SLE did not. OP0279 #EULAR2022 @rheumnow https://t.co/o3Ehp55C4Q
Poster Hall